CAMP4 Therapeutics Corp
CAMP
View Detailed Chart
4.000USD
-0.310-7.19%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
78.02MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-7.19%
5 Days
-14.71%
1 Month
-9.40%
6 Months
+33.33%
Year to Date
-34.75%
1 Year
-6.76%
View Detailed Chart
TradingKey Stock Score of CAMP4 Therapeutics Corp
Currency: USD Updated: 2026-03-27Key Insights
CAMP4 Therapeutics Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 100 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.75.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CAMP4 Therapeutics Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
CAMP4 Therapeutics Corp Highlights
StrengthsRisks
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 899.43% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.50M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.50M.
Fairly Valued
The company’s latest PE is -1.63, at a medium 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 1.67M shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
8.750
Target Price
+91.89%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
CAMP4 Therapeutics Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
CAMP4 Therapeutics Corp Info
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
Ticker SymbolCAMP
CompanyCAMP4 Therapeutics Corp
CEOMandel-Brehm (Josh)
Websitehttps://www.camp4tx.com/
Related Instruments
+0.96%
+1.56%
+0.85%
+2.90%
-1.28%
+1.78%
+1.47%
+0.07%
+0.00%
+2.70%
-2.08%
-0.13%
+0.72%
+2.03%
+2.33%
0.00%
+1.57%
-0.13%
+2.63%
+2.01%Popular Symbols
246.630
-2.170 (-0.87%)
165.170
-2.350 (-1.40%)
67232.000
+610.600 (+0.92%)
251.670
-23.670 (-8.60%)
2035.990
+15.290 (+0.76%)
355.280
-6.550 (-1.81%)
4538.230
+27.450 (+0.61%)
104.021
-0.241 (-0.23%)
1.147
+0.001 (+0.05%)
159.777
+0.118 (+0.07%)
